Loading...
•
Sep 30, 2023
Amneal Q3 2023 Earnings Report
Reported strong double-digit revenue and adjusted EBITDA growth and raised full year guidance.
Key Takeaways
Amneal Pharmaceuticals reported a strong Q3 2023 with a 14% increase in net revenue to $620 million and a 22% increase in adjusted EBITDA to $154 million. Net income attributable to Amneal Pharmaceuticals, Inc. was $10 million, compared to a net loss of $3 million in the third quarter of 2022. Diluted EPS was $0.06, and adjusted diluted EPS was $0.19. The company affirmed its previously announced increased full-year guidance.
Net revenue for Q3 2023 was $620 million, a 14% increase compared to Q3 2022.
Net income attributable to Amneal Pharmaceuticals, Inc. was $10 million in Q3 2023, compared to a net loss of $3 million in Q3 2022.
Adjusted EBITDA for Q3 2023 was $154 million, a 22% increase compared to Q3 2022.
Diluted EPS for Q3 2023 was $0.06, compared to a loss of $0.02 for Q3 2022.
Revenue by Segment
Forward Guidance
Amneal affirmed its previously announced increased 2023 full year guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...